ADVERSE DRUG REACTIONS AMONG DRUG-RESISTANT TUBERCULOSIS TREATMENT: AN OBSERVATIONAL COHORT STUDY

LEYA P. BABU; NIMMY ROBIN; JOHNSON V. BABU; JOICY JOSE; SHAJI GEORGE

doi:10.22159/ijpps.2021v13i9.42460

Authors

LEYA P. BABU Pharm. D Interns. Nirmala College of Pharmacy, Muvattupuzha, Kerala 686661
NIMMY ROBIN Pharm. D Interns. Nirmala College of Pharmacy, Muvattupuzha, Kerala 686661
JOHNSON V. BABU Pharm. D Interns. Nirmala College of Pharmacy, Muvattupuzha, Kerala 686661
JOICY JOSE Pharm. D Interns. Nirmala College of Pharmacy, Muvattupuzha, Kerala 686661
SHAJI GEORGE Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala 686661

DOI:

https://doi.org/10.22159/ijpps.2021v13i9.42460

Keywords:

Adverse drug reaction, Drug resistance TB, Causality assessment, Severity assessment

Abstract

Objective: Adverse drug reaction (ADR) is regarded as one of the major challenges in the treatment of drug-resistant tuberculosis (DR-TB). It can lead to non-compliance or interrupting treatment completion, which can contribute to avoidable morbidity, drug resistance, treatment failure, reduced quality of life, or mortality.

Methods: A retrospective cohort study was conducted in the Ernakulam district of Kerala from 2016 to 2019. All DR-TB patients registered under the DR-TB center were enrolled in the study. Due to privacy and confidentiality HIV infected patients and patients below 12 y of age were excluded in this study and only the data with ADR reported by patients is collected from medical records.

Results: Out of the total 146 patients, about 75 % of patients experienced at least one ADR during treatment, and a total of 208 ADRs were reported. Among all the ADRs, the most common ADR was gastritis (12.98%) followed by ototoxicity (10%) and vomiting (5.76%), etc. It was found that males (78.76%) within the age group 46-65 y exhibited more ADR than females. Some of the ADR requires drug withdrawal and replacement with other drugs and most of the patients also needed symptomatic treatment without modifying the treatment regimen. All ADR reported were collected and causality assessment was done via WHO and Naranjo scale. The majority of ADR belongs to the “probable” category in the WHO scale and Naranjo scale. The evaluation of the severity of ADR by using the Modified Hartwig and Siegel scale indicated that most of the ADR was of moderate level showing a 4b reaction. The study also assessed the preventability of ADR using the Schumock and Thornton preventability scale.

Conclusion: Many of the ADRs were unidentified or not reported due to several reasons like milder ADR, patient lack of knowledge, Negligence of symptoms, unawareness of health providers, etc. Whereas the long-term treatment and diversities in age, gender, etc. were found as major contributors to ADR along with comorbidities. New drugs in combination with existing drugs created the potential for previously unnotified reactions. Pharmacovigilance should address the safety of therapy and identify ADRs, especially the serious ones with routine monitoring to prevent mortality, morbidity, and other negative outcomes.

Downloads

Download data is not yet available.

References

Kurz SG, Furin JJ, Bark CM. Drug-resistant tuberculosis: challenges and progress. Infectious Disease Clin 2016;30:509-22.

World Health Organization. Stop TB Initiative (World Health Organization). Treatment of tuberculosis: guidelines. World Health Organization; 2010.

Nusrath Unissa A, Hanna LE, Swaminathan S. A note on derivatives of isoniazid, Rifampicin, and pyrazinamide showing activity against resistant Mycobacterium tuberculosis. Chem Biol Drug Des 2016;87:537-50.

Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc 2019;66:520-32.

Amin S, Mishra V, Mira D, Rajesh S. Pattern of adverse drug reactions and its potential impact on drug-resistant tuberculosis patients at a tertiary care teaching hospital in Western India. Clin J Pharmacol Pharmacother 2018;1:15-20.

Shinde MP, Halasawadekar NR, Ramanand SJ, Pore SM, Ramanand JB, Patil PT, et al. A study of adverse drug reactions in patients receiving treatment for multi-drug resistant tuberculosis. Int J Basic Clin Pharmacol 2017;34:354-8.

Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second-line anti-TB treatment in Mumbai, India. PloS One 2012;11:e40781.

Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, et al. Putting in harm to cure: drug-related adverse events do not affect the outcome of patients receiving treatment for multidrug-resistant tuberculosis. Experience from a tertiary hospital in Italy. PloS One 2019;14:e0212948.

Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterranean J Hematol Infectious Diseases 2014;6:e2014061.

Mehari K, Asmelash T, Hailekiros H, Wubayehu T, Godefay H, Araya T, et al. Prevalence and factors associated with multidrug-resistant tuberculosis (MDR-TB) among presumptive MDR-TB patients in tigray region, Northern Ethiopia. Canadian J Inf Diseases Med Microbiol 2019;1-8. https://doi.org/10.1155/2019/2923549.

Bistline KL. Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study from the introduction of bedaquiline in South Africa National TB Programme (Doctoral dissertation, University of Cape Town); 2018.

Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine 2017;96:e7482.

Shibeshi W, Sheth AN, Admasu A, Berha AB, Negash Z, Yimer G. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. BMC Pharmacol Toxicol 2019;20:31.

Kennedy NA, Oluwaseun A, Denis AD, Chukwuemeka SP. Cycloserine induced-psychosis in a 22-year old male pharmacy student: a case report. Am J Psychiatry Neurosci 2016;4:1-4.

Dere E, Zlomuzica A, Silva MD, Ruocco LA, Sadile AG, Huston JP. Neuronal histamine and the interplay of memory, reinforcement and emotions. Behavioural Brain Res 2010;215:209-20.

Jaramillo E. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization; 2008.

Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. Pharm Ther 2014;39:695-715.

Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-lnduced goitrous hypothyroidism. Annals Int Med 1984;100:837-9.

BJ MK, Mathew S, Ramesh S, Hymavathi R, Srikanth MS. Causality assessment of adverse drug reactions in tuberculosis patients who are on directly observed treatment short-course strategy in mysore district. Indian J Pharm Practice 2013;6:22-6.